Submissions from 2014
Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry, B. A. Steinberg, R. G. Blanco, D. Ollis, S. Kim, D. N. Holmes, P. R. Kowey, G. C. Fonarow, J. Ansell, B. Gersh, J. P. Piccini, and +6 additional authors
Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), B. A. Steinberg, S. Kim, G. C. Fonarow, L. Thomas, J. Ansell, P. R. Kowey, K. W. Mahaffey, B. J. Gersh, E. Hylek, Informed Outcomes Registry Better, and +6 additional authors
Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry, B. A. Steinberg, S. Kim, L. Thomas, G. C. Fonarow, E. Hylek, J. Ansell, A. S. Go, P. Chang, P. Kowey, E. D. Peterson, and +4 additional authors
American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort, M. B. Urowitz, D. D. Gladman, D. Ibanez, J. Sanchez-Guerrero, J. Romero-Diaz, C. Gordon, S. C. Bae, A. E. Clarke, C. Aranow, T. Stoll, and +22 additional authors
Does a genetic variant in FOXO3A predict a milder course of rheumatoid arthritis?, H. W. van Steenbergen, S. Rantapaa-Dahlqvist, J. A. B. van Nies, E. Berglin, T. W. J. Huizinga, P. K. Gregersen, and A. H. M. van der Helm-van Mil
A 129-kb Deletion on Chromosome 12 Confers Substantial Protection Against Rheumatoid Arthritis, Implicating the Gene SLC2A3, C. D. Veal, K. E. Reekie, J. C. Lorentzen, P. K. Gregersen, L. Padyukov, and A. J. Brookes
Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation", L. Wallentin, R. D. Lopes, M. Hanna, L. Thomas, A. Hellkamp, S. Nepal, E. M. Hylek, S. M. Al-Khatib, J. Ansell, C. B. Granger, and +23 additional authors
Pathogenetic role of glomerular CXCL13 expression in lupus nephritis, K. Worthmann, F. Gueler, S. von Vietinghoff, A. Davalos-Militz, F. Wiehler, A. Davidson, T. Witte, H. Haller, M. Schiffer, L. Schiffer, and +1 additional author
Submissions from 2013
Moving forward in GME reform: a 4 + 1 model of resident ambulatory training, S. I. Chaudhry, S. Balwan, K. A. Friedman, S. Sunday, B. Chaudhry, D. DiMisa, and A. Fornari
Aging in Suburbia: An Assessment of Senior Needs, R. Pekmezaris, A. Kozikowski, G. Moise, P. A. Clement, J. Hirsch, J. Kraut, and L. C. Levy
Submissions from 2012
Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: a meta-analytic review., D. Edmondson, S. Richardson, L. Falzon, K. W. Davidson, M. A. Mills, and Y. Neria
Submissions from 2011
P2Y12 antagonists in acute coronary syndrome: In whom should they be started, and when?, C. W. Good and P. B. Berger
Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: A post-hoc analysis from the ISAR-REACT 3 trial, A. A. Khattab, G. Ndrepepa, S. Schulz, F. J. Neumann, J. Mehilli, H. J. Büttner, J. Pache, M. Seyfarth, P. B. Berger, G. Richardt, and +3 additional authors
Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: Insights from the sos (stenting of saphenous vein grafts) trial, T. T. Michael, A. R. R. Abdel-Karim, A. Papayannis, C. Lichtenwalter, J. A. De Lemos, O. Obel, T. Addo, M. Roesle, P. B. Berger, E. S. Brilakis, and +11 additional authors
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a verifynow P2Y12 assay: Impact on thrombosis and safety (GRAVITAS) trial, M. J. Price, D. J. Angiolillo, P. S. Teirstein, E. Lillie, S. V. Manoukian, P. B. Berger, J. F. Tanguay, C. P. Cannon, and E. J. Topol
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: An angiographic substudy of the ASSENT-4 PCI (assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention) trial, J. Zalewski, K. Bogaerts, W. Desmet, P. Sinnaeve, P. Berger, C. Grines, T. Danays, P. Armstrong, and F. Van De Werf